Sanofi Partner ADEL Pulls 54 Billion Won Kosdaq IPO as Korean Listings Freeze
The Alzheimer's antibody developer backed by Korea Development Bank and Stonebridge funds scrapped its Dec. 2 listing after institutions bid below its range.

What to know
- ADEL filed to withdraw its Kosdaq IPO on Nov. 20, citing difficulty getting a fair valuation, after bookbuilding from Nov. 12 to 18.
- The Alzheimer's drug developer had sought 39.1 billion to 54.3 billion won by selling 2.17 million new shares at 18,000 to 25,000 won each.
- Eighteen Korean companies excluding SPACs have halted listing plans this year, CBC News reported, citing Korea Exchange KIND data.
SEOUL
ADEL, a Seoul biotech startup that licensed an Alzheimer's antibody to Sanofi last year, withdrew its planned Kosdaq listing on Friday after most institutional investors bid below its price range. The company had aimed to raise as much as 54.3 billion won and list on Dec. 2.
In a withdrawal statement filed with the Financial Services Commission on Nov. 20, ADEL said it had cancelled the remaining schedule after consulting its joint lead managers, citing difficulty in getting the company's value properly assessed under current conditions. Because the decision came before retail subscriptions opened, the filing said, no investors had bought shares and there was no investor-protection issue.
For venture funds in Asia, the decision matters beyond one drug developer. ADEL carried a licensing deal with a global drugmaker and passed the Korea Exchange's preliminary review without trouble, yet still could not clear institutional pricing. Its backers, which include a state policy bank and several venture funds, now have to wait longer for an exit.
A deal that fell short in bookbuilding
ADEL planned to sell 2.17 million new shares at 18,000 to 25,000 won each, raising 39.1 billion to 54.3 billion won, according to Financial Consumer News and NEWSTOP. That would have valued the company at 389.9 billion to 541.5 billion won. Bookbuilding ran from Nov. 12 to 18, with retail subscriptions planned for Nov. 23 and 24.
Most institutions bid below the bottom of that range, the Seoul Economic Daily and NEWSTOP reported. The Seoul Economic Daily said the low end of the range was roughly in line with the valuation ADEL won in a pre-IPO round earlier this year, so pricing any lower would have left those investors with a loss. It named Samsung Securities and Mirae Asset Securities as lead managers.
The registration statement had been filed on Oct. 12 and amended on Oct. 27 and Nov. 11, according to the withdrawal filing.
ADEL develops antibodies that target the disease-causing forms of proteins linked to Alzheimer's while sparing their normal forms. In December 2025 it licensed its tau antibody, ADEL-Y01, to Sanofi in a deal worth up to $1.04 billion, Hit News and the Seoul Economic Daily reported. NEWSTOP said the upfront payment was $80 million, and that ADEL keeps about 47.7% of licensing income after sharing with co-developer Oscotec. ADEL had no operating revenue through the third quarter, according to NEWSTOP.
Who is waiting for an exit
Policy lenders and private funds owned more than 40% of ADEL before the offering, Financial Consumer News reported. Korea Development Bank was the largest single institutional holder at 12.77%, followed by a Yuanta private equity vehicle focused on biotech at 7.67%. Four Stonebridge investment funds held 15.34% between them, while Smilegate's innovation growth fund held 4.12% and a STIC fund held 2.55%, the outlet said.
Financial Consumer News said major financial investors appeared to have pressed for a later listing date, wary that a low price or a post-listing slump would cut the value of their stakes.
The company says it does not need the money right away. ADEL held about 100 billion won in current assets at the end of September, Hit News reported, and a company official told the outlet that clinical and research timelines would not slip. The official said a new registration statement could come as early as December but more likely in January or early February, depending on the market.
Timing is on ADEL's side for now. Its preliminary approval from the Korea Exchange, granted in early October, stays valid for six months, the Seoul Economic Daily reported, so it can return without another review until about April. ADEL is also in licensing talks with several global drugmakers for its ApoE4 antibody, ADEL-Y04, and is running scientific due diligence with the most advanced of them, Hit News reported. The company is targeting a deal in 2027.
A wider chill on Korean listings
ADEL is the fourth Korean company to withdraw an IPO this year after starting its offering, following JNTG, C&M and OLED materials maker SFC, the Seoul Economic Daily reported. Counting companies that dropped out at the preliminary review stage, 18 firms excluding SPACs have halted listing plans this year, CBC News reported, citing Korea Exchange KIND data.
Companies that pressed ahead have had to give ground. 5G private network specialist Ucast cut its range under a regulator's request and priced at 19,000 won, then drew retail orders of only about 0.5 times the shares on offer on Nov. 18 and 19, according to CBC News. The outlet said it was the first undersubscribed retail tranche in a Korean IPO since TEMC in January 2023. Drug developer Nex-I priced at 8,000 won, below its range, and closed its first day of trading 39.88% under that price, CBC News and NEWSTOP reported.
Venture-backed listings in Korea had already been uneven this month. AI software developer Lablup ended its Kosdaq debut 25% below its IPO price. The next date for ADEL's backers is the refiling window: a new registration statement before the preliminary approval lapses in April would let the company return to bookbuilding without starting the review again.
Sources
- Financial Supervisory Service DART: 철회신고서 (Withdrawal statement), ADEL Inc. (Nov. 20, 2026)
- Seoul Economic Daily: 아델도 코스닥 IPO 철회…공모주 잔혹사 이어진다 [시그널] (Nov. 20, 2026)
- Hit News: 아델, IPO 철회에도 '차질없다'…"내년 1~2월 전후 재추진" (Nov. 20, 2026)
- Financial Consumer News: 산은이 투자한 '아델'도 못 버텼다…수요예측 부진에 상장 철회 (Nov. 20, 2026)
- CBC News: [IPO한파] 아델·에스에프씨 줄줄이 철회하고 넥스아이는 첫날 39% 급락… 얼어붙은 공모주 투심 어디까지? (Nov. 21, 2026)
- NEWSTOP: ADEL Withdraws KOSDAQ IPO After Weak Bookbuilding (Nov. 20, 2026)
Our standards: Capital Times reports under the principles set out in our Editorial Standards and Ethics Policy. Spotted an error? Report it to our editors.







